Dr Mario Sznol talks to ecancer at ASCO 2013 about long-term follow-up results from an expanded phase I study examining the effects of nivolumab in advanced melanoma. 107 patients were treated with five different doses of nivolumab. All patients had disease that worsened despite prior standard systemic therapies — 25 percent had three or more prior therapies and 63 percent had two or more. Overall, 33 out of 107 (31 percent) of patients experienced tumor shrinkage of at least 30 percent and...

Dr Swchwartz gives ecancertv his ASCO 2013 highlights. He covers the latest promising news in melanoma and comments on the potential of immunotherapy and antibodies for treatment of other cancers.

Dr Matthew Ellis talks to ecancer at ASCO 2013 about the affects of The Cancer Genome Atlas on research, treatment and next generation sequencing.

Prof Jedd Wolchok talks to ecancer at the 2013 ASCO Annual Meeting about a phase I study that involved the drug combination ipilimumab and nivolumab in melanoma. In cases of melanoma, ipilimumab impacts overall survival and nivolumab provides durable responses. Prof Wolchok explains the design of the trials and how using these drugs in combination target the PD1 trigger.

Dr Stephen Ansell talks to ecancer at ASCO 2013 about rituximab vedotin, an anti-CD30 chemotherapy agent, which allows for chemotherapy to be administered directly into malignant cells. Rituximab vedotin has shown promising results in lymphoma as a single agent and is currently in clinical trials investigating use in combination in the frontline setting.

Dr Keiichi Fujiwara talks to ecancer at ASCO 2013 about the efficacy of Z100, an immunomodulator that has been in development in Japan since 1966, and its ability to be used in combination with very low rates of toxicity.

Dr Emiel J. Rutgers talks to ecancer at ASCO 2013 on a European phase III clinical trial called AMAROS. The study found that axillary radiotherapy (ART) and lymph node surgery (axillary lymph node dissection, ALND) resulted in equivalent overall and disease-free survival at five years after treatment for women with sentinel lymph node positive early breast cancer. However, a debilitating side effect known as lymphoedema was twice as common among women who underwent surgery.

Dr Robert Mansel talks to ecancer at ASCO 2013 about the AMAROS trial which investigated complete axillary lymph node dissection with axillary radiation therapy in treating women with invasive breast cancer.

Dr Garrett Brodeur talks to ecancer at the 2013 ASCO Annual Meeting in Chicago about childhood cancer neuroblastoma, ALK and being awarded ASCO's Pediatric Oncology Award.

Dr Ansell talks to ecancertv at ASCO 2013 about the tumour microenvironment and stroma and its role in cancer. He covers antibodies and immunotherapy tackling lymphnodes and ALK positive cells.

Dr Ramalingam gives a comment at ASCO 2013 on two papers published in the New England Journal of Medicine confirming crizotinib as superior to chemotherapy for the treatment of previously treated, advanced non-small cell lung cancer (NSCLC) with ALK rearrangement.

Dr Hecht talks to ecancer at ASCO 2013 about the Translational Research in Oncology (TRO) collaboration using lapatinib in combination with chemotherapy.

Dr Marjorie G. Zauderer talks to ecancer at the 2013 ASCO Annual Meeting about progression free survival in lung cancer patients with KRAS mutation and elevated LDH and the GALAXY-1 trial.

Dr G Thomas Budd talks to ecancer at the 2013 ASCO Annual Meeting in Chicago on a phase III randomised clinical trial that found low-dose weekly administration of paclitaxel and standard dose, every two weeks administration, resulted in equal progression-free survival for women with higher-risk early-stage breast cancer who have undergone surgery. However, researchers found that certain side effects were more common with the every two weeks regimen, suggesting the weekly schedule may be...

Dr Andreas du Bois talks to ecancer at ASCO 2013 about the phase III clinical trial in women with advanced ovarian cancer that found treatment with the oral targeted drug pazopanib following initial successful chemotherapy extended disease-free survival by an average of 5.6 months, compared to placebo. Pazopanib is an oral drug that blocks several targets involved in the growth of tumors and their blood vessels (angiogenesis). In the study, 940 patients with stage III/IV ovarian, fallopian...

Dr Volke Heinemann talks to ecancer managing editor, Prof Gordon McVie, at ASCO 2013 about the German phase III clinical trial FIRE-3. The study found that first-line cetuximab plus FOLFIRI chemotherapy (folinic acid, fluorouracil, irinotecan) offers a roughly four-month survival advantage for patients with metastatic colorectal cancer, compared with bevacizumab plus FOLFIRI. The targeted drugs cetuximab and bevacizumab, both in combination with chemotherapy, are approved and commonly used...

Dr Roy Herbst talks to ecancer at the 2013 ASCO Annual Meeting about exciting research presented at the meeting, including use of immunotherapy in melanoma and his colleague's, Dr Mario Sznol, research on melanoma.